Post-Vaccination Microclots: What the Spike-Fibrin Research Shows

This review is for people with persistent symptoms after COVID-19 vaccination who want to know what the microclot research actually says, without dismissal in one direction or overstatement in the other. The question here is narrow and mechanistic: if specific spike-derived amyloid fibrils can make fibrin harder to dissolve, is it reasonable to ask whether the same sequence produced after vaccination could do something similar in some people?

That's a research question, not a population risk-benefit claim, and not a statement that infection and vaccination are interchangeable exposures.

The question in one paragraph

Westman and colleagues showed in 2025 that Spike685 amyloid fibrils make fibrin clots resist plasmin in a purified system (Westman et al., 2025). Earlier work had found that recombinant spike S1 induces fibrin(ogen) resistant to fibrinolysis in plasma (Grobbelaar et al., 2021). Because mRNA vaccines encode the same spike framework that contains that amyloidogenic region, researchers have asked whether overlapping clot pathology turns up in symptomatic recipients. The evidence sits across three tiers: in vitro biophysics, Long COVID cohorts, and a small number of post-vaccination studies.

Clinical next step

Want to see whether amyloid-positive microclots show up in your sample?

Our at-home amyloid fibrin test reports what Thioflavin T microscopy observes in your blood. It's informational data for you and your clinician, not a diagnosis.

Start screening

Start with the vocabulary

What is a fibrinaloid?

A fibrinaloid is an amyloid-like fibrin microclot, roughly 1 to 200 micrometres across, that resists normal plasmin-mediated breakdown. In the literature these deposits are described as amyloid-positive with dyes such as Thioflavin T, structurally abnormal under microscopy, and capable of trapping inflammatory molecules (Kruger et al., 2022).

That doesn't mean every small clot seen after COVID or vaccination is a fibrinaloid. It describes one specific kind of material that's been studied repeatedly. Our research summary on fibrin amyloid microclots covers how they're characterized.

What is Spike685?

Spike685 is a 17-amino-acid segment spanning residues 685 to 701, sitting immediately after the furin cleavage site of the spike protein. Among the seven spike-derived amyloid peptides Westman and colleagues tested, it was the one that most strongly impaired fibrinolysis.

What does post-vaccination syndrome mean here?

Different papers use different labels: post-vaccination syndrome, PACVS, longvax, PV/PIS. The 2026 cohort paper by Waters and colleagues used Post-Vaccination/Post-Infection Syndrome deliberately, because unrecognised asymptomatic infection before or after vaccination couldn't be excluded in their participants (Waters et al., 2026).

Naming that limitation out loud is good practice, and it's worth noticing which papers do it.

What the Westman paper showed

The team used purified components of the coagulation cascade rather than patient samples, testing seven amyloidogenic spike peptides against the fibrinogen-fibrin-fibrinolysis pathway.

• Five of seven spike amyloid fibrils didn't substantially interfere.
• Spike601 impaired thrombin-mediated fibrin formation by binding and sequestering fibrinogen, without affecting fibrinolysis.
• Spike685 produced the strongest fibrinolysis-resistant result, with dose-dependent resistance across fibril concentrations of 1.4 to 20 micrograms per millilitre, dense fibrin networks, and residual fibrin that colocalized with spike amyloid.

That gives the paper real mechanistic weight. It identifies a specific region of spike that changes fibrin behaviour in a specific direction, rather than asserting a vague association.

What the Westman paper did not show

It didn't show that every Long COVID patient has Spike685-driven clot pathology, that the in vitro concentrations match human tissue microenvironments, or that vaccinated patients were studied at all. No treatment targeting this mechanism was tested. It's a mechanistic bridge, not a clinical answer.

What the earlier microclot papers established

Three strands of earlier work set the stage.

Recombinant spike S1 added to normal plasma induced fibrin(ogen) changes associated with resistance to fibrinolysis, with amyloid-sensitive staining (Grobbelaar et al., 2021). That suggested live virus wasn't required to see a spike-related fibrin effect.

Long COVID cohorts showed persistent clotting protein abnormalities and increased antiplasmin (Pretorius et al., 2021), with follow-up work describing fibrin amyloid microclots and platelet pathology (Pretorius et al., 2022). Our plain-language guide to amyloid microclots in Long COVID summarizes that body of work.

Proteomic analyses found the deposits entrap inflammatory and coagulation-related proteins, suggesting they're biologically active rather than inert debris (Kruger et al., 2022).

Why vaccination entered the discussion

The defensible version of the argument runs through sequence, not dose.

1. A specific spike-derived amyloid peptide can make fibrin harder to dissolve in vitro.
2. Spike protein exposure can induce fibrin(ogen) abnormalities in plasma.
3. mRNA vaccines are spike-based platforms encoding that same region.

In their discussion, Westman and colleagues note that spike protein expression is the common component of SARS-CoV-2 infection and most COVID vaccination regimens. They also raise the possibility that original mRNA constructs, which retained the furin cleavage site while using the 2P prefusion-stabilizing mutations, could reach what they call a vulnerable aggregation-prone state after cleavage and S1 shedding. They present that explicitly as a hypothesis, not a demonstrated vaccine-cohort result.

The distinction matters. "The same sequence gives a plausible route to similar fibrin pathology" is supportable. "Therefore every persistent illness after vaccination is explained" is not.

Why the shared-sequence argument beats the exposure argument

You'll see the claim that vaccinated people categorically had higher spike exposure than people with Long COVID. That isn't established well enough to state as fact.

Infection involves replicating virus and highly variable viral burden. Vaccination involves non-replicating spike expression whose tissue distribution, duration and local concentration also vary. Antibody titres aren't a clean proxy for pathogenic spike burden, a point our article on spike antibody versus antigen testing goes into at length. And symptomatic post-vaccination cohorts remain small and heterogeneous.

The stronger claim is simply that the proposed mechanism is driven by the spike sequence itself, so the pathway is in principle available outside replicating infection. That keeps the question serious and the argument honest.

What the post-vaccination cohorts found

The 2026 PV/PIS proteomics study

Waters and colleagues analyzed digested microclot deposits from platelet-poor plasma in 14 PV/PIS participants and 16 healthy controls, using liquid chromatography mass spectrometry (Waters et al., 2026).

They reported significant alterations in coagulation factors, acute phase proteins and immune response modulators, including elevated serum amyloid A1 and A2, attractin, and coagulation factors X and XI, alongside downregulation of immune-regulatory proteins. Their conclusion was that PV/PIS is characterised by persistent immune dysregulation and coagulopathy.

Two caveats come from the authors themselves. The proteomic signature only partially overlapped the one previously reported in Long COVID samples collected before vaccines were available. And unrecognised infection couldn't always be excluded, which drove their choice of the PV/PIS label.

The 2025 Yale LISTEN preprint

A decentralized cross-sectional study of 42 participants reporting chronic illness after vaccination and 22 controls found differences in immune profiles, more frequent serological evidence of recent Epstein-Barr virus reactivation, and elevated circulating spike protein compared with controls (Bhattacharjee et al., 2025). It's a preprint, it's cross-sectional, and the authors frame the findings as warranting further investigation rather than as a diagnostic signature.

The 2025 Heliyon review

Halma and Varon argue that post-vaccination syndrome deserves recognition as a research and care problem, discussing microclot formation among several candidate mechanisms (Halma & Varon, 2025). It's useful for context and for its emphasis on rigorous diagnostic criteria, but it's a review article, not a causal cohort study.

How should you hold the evidence?

There's a real difference between a mechanism being real, being common, and explaining most cases. Those are three separate questions, and only the first has decent support.

Why this matters clinically

If persistent symptoms after vaccination can involve an overlapping fibrin-microclot pathway, a few things follow. Clinicians shouldn't assume the symptoms are psychogenic. Researchers should phenotype these patients with the same seriousness given to Long COVID. Studies should work harder to separate prior infection, vaccination timing and symptom onset. Biomarker work should be tied to outcomes rather than theory.

For what's been studied on the treatment side, our review of nattokinase and lumbrokinase research on microclots covers the enzyme literature honestly, and the directory of microclot testing labs and treatment centers lists where this work is being done. A wider set of claims about mRNA vaccine harms, and the evidence tiers behind them, is covered in our walkthrough of the 2025 JPandS review.

Where testing fits

Microclot microscopy observes whether amyloid-positive clot material is present. It doesn't attribute that material to a particular exposure and it isn't a diagnosis. Our at-home amyloid test stains a finger-prick dried blood sample with Thioflavin T and returns a Videographic Microscopy Report you can share with any provider. It doesn't measure circulating spike protein, and it doesn't quantify D-dimer or fibrinogen.

The pillar guides on amyloid fibrin testing and types of amyloid tests are the place to start if you want to understand what each available test can and can't tell you.

The cleanest summary

Westman's Spike685 result makes the overlap question sharper. The PV/PIS cohort makes it harder to dismiss. What's left is working out who actually fits that biology, how often it happens, and what interventions genuinely help. Anyone claiming those questions are already settled, in either direction, is ahead of the data.